GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dominari Holdings Inc (FRA:BP2A) » Definitions » Shiller PE Ratio

Dominari Holdings (FRA:BP2A) Shiller PE Ratio : (As of May. 31, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Dominari Holdings Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Dominari Holdings Shiller PE Ratio Historical Data

The historical data trend for Dominari Holdings's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dominari Holdings Shiller PE Ratio Chart

Dominari Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dominari Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dominari Holdings's Shiller PE Ratio

For the Biotechnology subindustry, Dominari Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dominari Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dominari Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Dominari Holdings's Shiller PE Ratio falls into.



Dominari Holdings Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Dominari Holdings's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Dominari Holdings's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.837/131.7762*131.7762
=-0.837

Current CPI (Mar. 2024) = 131.7762.

Dominari Holdings Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -697.132 100.560 -913.543
201409 -191.744 100.428 -251.597
201412 -86.733 99.070 -115.367
201503 -180.917 99.621 -239.312
201506 -1,722.668 100.684 -2,254.647
201509 -100.425 100.392 -131.820
201512 313.056 99.792 413.392
201603 -16.869 100.470 -22.125
201606 592.226 101.688 767.457
201609 -7.081 101.861 -9.161
201612 -134.246 101.863 -173.669
201703 -12.835 102.862 -16.443
201706 -24.435 103.349 -31.156
201709 4.849 104.136 6.136
201712 -9.768 104.011 -12.376
201803 -13.236 105.290 -16.566
201806 -2.910 106.317 -3.607
201809 -13.695 106.507 -16.944
201812 43.932 105.998 54.616
201903 -2.018 107.251 -2.479
201906 -4.514 108.070 -5.504
201909 -21.302 108.329 -25.913
201912 10.404 108.420 12.645
202003 -14.000 108.902 -16.941
202006 -1.057 108.767 -1.281
202009 -0.866 109.815 -1.039
202012 0.699 109.897 0.838
202103 -1.000 111.754 -1.179
202106 -0.216 114.631 -0.248
202109 -0.009 115.734 -0.010
202112 -0.301 117.630 -0.337
202203 -1.135 121.301 -1.233
202206 -1.116 125.017 -1.176
202209 -1.182 125.227 -1.244
202212 -1.246 125.222 -1.311
202303 -0.663 127.348 -0.686
202306 -1.652 128.729 -1.691
202309 -0.618 129.860 -0.627
202312 -1.183 129.419 -1.205
202403 -0.837 131.776 -0.837

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dominari Holdings  (FRA:BP2A) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Dominari Holdings Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Dominari Holdings's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dominari Holdings (FRA:BP2A) Business Description

Traded in Other Exchanges
Address
One Rockefeller Plaza, 11th Floor, New York, NY, USA, 10020
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Dominari Holdings (FRA:BP2A) Headlines

No Headlines